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between days 45 and 100. Median age was 34 years (range 10-56);
78 had standard risk (SR) disease in ﬁrst remission or ﬁrst chronic
phase of CML, the remaining 79 had high risk (HR) disease. The
day 30 post-transplant lymphocyte count (LC30) was available in
154 patients and day 30 lymphocyte subset analysis was performed
in 54. Median LC30 was 400/	l, (range 10-3295) and 150/	l,
(range 6-1005) for CD56, CD16 CD3- NK cells (NK30).
Eighty-ﬁve patients (514%) survive (median 1392 days). Patients
with LC30 above median had signiﬁcantly (p0.002) faster neu-
trophil engraftment (18 vs.13 days), platelet engraftment (22 vs.18
days) and signiﬁcantly fewer febrile days before day30 pos-trans-
plantation (8.6 vs. 5). Patients with  median LC30 had signiﬁ-
cantly better transplant outcome: survival 71 vs. 36 p0.0001; DFS
71 vs. 31 %, p0.001; NRM 10 vs. 38, p0.001; relapse 22 vs. 51
%, p0.004;  II aGVHD 34 vs. 51 p0.05. In multivariate
analysis only disease risk and LC30 emerged as independent prog-
nostic factors: LC30 above 400/	l was associated with improved
survival (RR 4.3), DFS (RR 4.5), less relapse (RR 10.3), NRM (RR
3.3) and aGVHD (RR 2.3). LC30 impacted outcome of both HR
and SR disease groups. In the subset of 54 patients where NK cells
were quantitated LC30 and NK30 were highly correlated
(p0.001) and NK30 above 150/	l was also associated with im-
proved transplant outcome: In multivariate analysis, SR disease and
NK30 150/	l were the only independent factors associated with
better survival (RR 3), DFS (RR 3), less relapse (RR 4.8), less NRM
(RR 3) and less aGVHD (RR 5.3). This study did not deﬁne
whether LC30 is a surrogate for NK cell count or whether both are
a surrogate for another undetected prognostic factor. However the
inverse relationship between NK count and aGVHD raise the
possibility of an NK-mediated effect occurring via elimination of
host antigen presenting cells as described by others.
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TREATMENT OF STEROID-RESISTANT GRAFT-VERSUS-HOST DISEASE
WITH MONOCLONAL ANTIBODIES IN CHILDREN
Schechter, T.1, Afzal, S.1, Finkelstein, Y.1, Koren, G.1, Doyle, J.1,
Dupuis, L.L.1 1The Hospital for Sick Children, Toronto, ON, Canada.
Introduction: Acute graft-versus-host disease (aGVHD) carries
a major risk of morbidity and mortality in patients undergoing
hematopoietic stem cell transplantation (HSCT). The prognosis is
poor if aGVHD does not respond to corticosteroid treatment.
Recently, monoclonal antibodies such as daclizumab, a humanized
monoclonal IgG1, and inﬂiximab, a chimeric monoclonal antibody
that binds the precursor of tumor-necrosis factor-alfa, have shown
promising results in the treatment of corticosteroid-resistant
aGVHD. The reported complete response rate to monoclonal
antibody therapy in adults with aGVHD reaches as high as 47%.
Data describing the efﬁcacy of monoclonal antibodies in children
with corticosteroid-resistant aGVHD are limited.
Methods: We conducted a retrospective analysis to evaluate the
efﬁcacy of daclizumab and/or inﬂiximab in children diagnosed with
steroid-resistant aGVHD in the Hospital for Sick Children, To-
ronto, from July 2002 to December 2005. Corticosteroid-resistant
aGVHD was deﬁned as aGVHD which did not response or wors-
ened after a minimum of 5 days of corticosteroid therapy. Com-
plete response (CR) was deﬁned as full recovery without any signs
of aGVHD; partial response (PR) was deﬁned as improvement of
aGVHD symptoms in at least one organ without worsening in
other organs.
Results: Sixteen children were treated for aGVHD, twelve of
them had aGVHD grade 3 or 4. The organs involved were gut
(n6), skin (n4), liver (n2) and multi-organ involvement (n4).
Eleven children were given daclizumab; one was treated with
inﬂiximab and 4 with their combination. Fourteen children re-
ceived a full course of monoclonal antibodies for aGVHD. An
additional child died after the ﬁrst dose and one child developed
reactive arthritis attributed to daclizumab. Eight of the 14 children
who completed treatment (57%) responded: ﬁve had CR and three
had a PR. Three children developed fatal fungal infection and one
had fatal adenovirus infection during or shortly after monoclonal
antibody treatment. Eight children died: Seven from Transplant
Related Mortality (TRM) and 1 due to relapse. Median length of
follow up in the remaining 8 patients was 20 months.
Conclusion: Monoclonal antibodies were effective in the treat-
ment of children with corticosteroid-resistant acute GVHD. The
risk for infection, mainly fungal, was high.
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MUTANT INOSINE MONOPHOSPHATE DEHYDROGENASE II PROVIDES
SELECTIVE ADVANTAGE TO TRANSDUCED CELL LINES ABOVE WILD
TYPE
Schroeder, M.A.1, Rettig, M.P.1, Ritchey, J.K.1, DiPersio, J.F.1 1Wash-
ington University School of Medicine, Division of Oncology, Saint Louis,
MO.
Nonmyeloablative conditioning regimens followed by allogeneic
hematopoietic cell transplantation relies on pre and post transplan-
tation immunosuppression to overcome host-versus-graft reactions
and control graft-versus-host-disease (GVHD). Lower donor chi-
merism predicts for higher rejection and relapse (Blood 2004;
104(8):2254). Immunosuppression may inhibit the beneﬁcial graft-
versus-infection and graft-versus-leukemia effects. Genetically
modifying T cells with a drug resistance gene is one way to confer
protection from the effects of immunosuppressive agents, retain
donor T cell function, and increase donor T cell chimerism.
Mycophenolate mofetil (MMF) has been used in the post trans-
plant setting to decrease GVHD and reduce host vs. graft reac-
tions. MMF’s active metabolite is mycophenolic acid (MPA),
which inhibits the enzyme inosine monophosphate dehydrogenase
(IMPDH). Its type II isoform is the rate-limiting enzyme in de
novo guanosine synthesis and is preferentially expressed in acti-
vated T and B cells. A number of investigators have identiﬁed
IMPDH II mutants that have altered MPA binding capacity and
normal guanosine synthetic activity ex vivo. We have generated six
mutants of IMPDH II and retrovirally transduced them into 3 cell
lines: human T cells (Jurkat), canine large granular lymphocytes
(CLGL-90) and ﬁbroblasts (NIH3T3). The mutants include:
S276A, S276F, T333I  S351Y (IY), L30F  Q277R, Q277R 
A462T, and S276Y. We generated bicistronic (IRES containing)
retroviral vectors that expressed either HA-tagged wild type hu-
man IMPDH II (WT) or an HA-tagged IMPDH mutant and
EGFP. Forced expression of WT will increase the MPA IC50 3
fold (IC50  3uM) compared to non-transduced cells. Forced
expression of only the IY mutant in all cell lines tested was able to
transfer resistance to MPA in excess of WT (IC5050uM). To
show that resistance was related to the expression of the mutant
enzyme we correlated GFP by FACS with HA-IMPDH II expres-
sion by western blot analysis, and correlated this with resistance to
MPA in vitro. This is the ﬁrst report where forced expression only
of the IY mutant provides a clear enhanced resistance to MPA in
vitro compared to cells over expressing wild type IMPDH II.
Currently, we are generating bicistronic maloney based oncoret-
roviral vectors which carry a suicide gene (CD34-TK) and the IY
mutant which will allow us to pharmacologically modulate the level
of donor T cells after allogeneic stem cell transplantation.
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DONOR C3435T POLYMORPHISM IN THE MULTIDRUG RESISTANCE 1
(MDR1) GENE IS ASSOCIATED WITH THE INCIDENCE OF ACUTE AND
CHRONIC GRAFT-VERSUS-HOST DISEASE (GVHD) AFTER ALLOGENEIC
HEMATOPOIETIC STEM-CELL TRANSPLANTATION (ALLOSCT)
Shimoni, A.1, Ostrovsky, O.1, Galski, H.1, Hardan, I.1, Shem-Tov, N.1,
Yerushalmi, R.1, Nagler, A.1 1Chaim Sheba Medical Center, Tel-
Hashomer, Israel.
GVHD is the most signiﬁcant complication of alloSCT. HLA,
KIR and cytokine gene polymorphisms are involved in determin-
ing the risk of GVHD. The current study was designed to explore
the role of MDR1 gene polymorphism in predicting GVHD.
Single nucleotide polymorphisms at C3435T and G2677T were
determined in patients (pts) and donors using RFLP- based assay
and correlated with the occurrence GVHD. The study included
115 pts with various hematological malignancies after alloSCT
from related (n73) or unrelated (n42) donors. Fifty pts had
myeloablative and 65 had reduced-intensity conditioning. C3435T
polymorphism included CC, CT and TT genotypes that were
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detected in 36, 47, and 17% of pts and 34, 47, and 19% of donors,
respectively. G2677T polymorphism included GG, GT and TT
genotypes that were detected in 29, 55, and 16% of pts and 34, 49,
and 17% of donors, respectively. The cumulative incidence of
acute GVHD grade III-IV was 38% (24-62), 18% (9-35) and 18%
(6-50), when the donors had CC, CT and TT in the C3435T site,
respectively (p0.02). Multivariable analysis determined donor
CC (HR 2.4, p0.05) and alloSCT from female to male (HR 5.1,
p0.03) as the most signiﬁcant factors predicting for severe acute
GVHD while donor, disease and conditioning type were not sig-
niﬁcant. The overall incidence of grade II-IV GVHD was not
statistically different between the genotypes. Pt C3435T polymor-
phism and pt or donor G2677T polymorphisms had no correlation
with GVHD. The cumulative incidence of chronic GVHD was
84% (95%CI, 68-100), 53% (38-75) and 38% (39-63) when the
donors had CC, CT and TT in the C3435T site, respectively
(p0.02). Multivariable analysis determined donor CC (HR 2.2,
p0.01), alloSCT from female to male (HR 2.5, p0.03) and
unrelated donor (HR 1.8, p0.05) as the most signiﬁcant factors
predicting for chronic GVHD. The CC genotype in C3435T is
known to be associated with higher expression level of P-glycop-
rotein (Pgp). We speculate that increased Pgp may result in lower
intracellular levels of cyclosporine in donor T-cells leading to
higher incidence of GVHD. Furthermore, Pgp may be involved in
transporting cytokines that are critical to the pathogenesis GVHD.
Further studies will be required to determine the mechanism of the
association of C3435T polymorphism, Pgp expression and
GVHD. In conclusion, C3435T polymorphism in the MDR1 gene
may be an important factor in predicting GVHD and may be
considered when selecting the most suitable donor.
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INFLUENCE OF KILLER IMMUNOGLOBULIN-LIKE RECEPTOR (KIR)
MATCHING ON THE DEVELOPMENT OF CHRONIC GRAFT-VS.-HOST
DISEASE (CGVHD) IN T-CELL DEPLETED MATCHED UNRELATED DO-
NOR (MUD) ALLOGENEIC BONE MARROW TRANSPLANTATION (AL-
LOBMT)
Sobecks, R.1, Askar, M.1, Ball, E.2, Rybicki, L.1, Thomas, D.1,
Bates, J.1, Kalaycio, M.1, Andresen, S.1, Pohlman, B.1, Dean, R.1,
Sweetenham, J.1, Maciejewski, J.1, Bolwell, B.1 1The Cleveland Clinic,
Cleveland, OH; 2London Health Sciences Centre, London, ON, Canada.
The reactivity of NK cells and some T cell populations is regu-
lated by KIR interactions with HLA class I molecules. Such inter-
actions have been suggested to inﬂuence outcomes after alloBMT.
However, the effect of KIR interactions on the development of
cGVHD after MUD alloBMT has not been well described. We
analyzed 30 pts who received a 12/12 HLA MUD T-cell depleted
myeloablative alloBMT at our institution from 5/5/95-2/6/04.
Diagnoses included 17 AML, 6 ALL, 4 CML and 3 MDS. GVHD
prophylaxis consisted of Tacrolimus and methotrexate (5 mg/m2
days 1, 3, 6 and 11). The median age was 40 (range, 19-58). KIR
genotypes were determined for donors by PCR-RSSOP analysis.
Recipient HLA KIR ligands were categorized as: 1) HLA-Cw
groups C1 ( or -); 2) C2 ( or -); 3) HLA-Bw4 ( or -); and 4)
HLA-A3 or -A11 ( or -) [as reviewed by Farag et al. Blood 2002;
100:1935-47]. Donor KIR genotype and recipient HLA KIR li-
gands were used to generate an inhibitory KIR score for pts from
1 to 4 corresponding to the potential number of donor inhibitory
KIRs engaged with recipient HLA KIR ligands. Eight pts had a
score of 1, 11 had a score of 2, 9 had a score of 3 and 2 had a score
of 4. The Kaplan-Meier method was used to estimate the achieve-
ment of cGVHD by inhibitory KIR score. Pts with a score of 1-2
compared to those with a score of 3-4 were more likely at 6 mos to
develop cGvHD (71% vs. 0%, respectively, p0.002)and extensive
cGvHD (48% vs. 0%, respectively, p0.06). Only 1 (9%) pt with
a score of 3-4 developed cGvHD (limited stage) at 29.9 mos while
7 (37%) with a score of 1-2 developed cGvHD (4 extensive stage)
at a median of 3.8 mos (range, 3.3-7.6). No differences were found
between these 2 groups regarding the development of grade 2-4 or
grade 3-4 acute GVHD or with regards to age, race, sex, number
of prior chemotherapies, disease status at BMT, preparative regi-
men, total nucleated and CD34 cell doses. Pts with lower inhib-
itory KIR scores may have more active anti-recipient, donor-
derived effector cells (NK cells and T cell subsets) that may result
in increased cGVHD. Conversely, those with higher inhibitory
KIR scores may have less active populations and be less likely to
develop cGVHD. Given the genotypic potential to inhibit all NK
cells KIR expression may be variable among different clones, and
may affect the development of cGVHD. Further investigation of
KIR expression at the cellular level rather than by genotyping
alone should be pursued.
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CHANGES IN LYMPHOCYTES AND REGULATORY T CELLS IN CHRONIC
GVHD
Tabellini, L.1, Haeusermann, P.1, Flower, M.E.1, Grogan, B.M.1,
Bumgarner, T.E.1, Damodaran, A.C.1, Martin, P.J.1, Hansen, J.A.1
1Fred Hutchinson Cancer Research Center, Seattle, WA.
Regulatory T cells (Treg) are believed to play an important role
in modulating the severity of GVHD and the development of
immunological tolerance after HCT. Studies reported here were
undertaken to determine in more detail the presence and activity of
Treg and interactions with other pathways known to affect regu-
latory function.
Ninety patients were enrolled between 6 and 198 months (me-
dian 19) post-HCT including 6 patients with no prior acute or
chronic GVHD, 64 with prior aGVHD, 72 who developed exten-
sive cGVHD and 18 who had been withdrawn from all immune
suppression therapies (IST). These 90 patients were classiﬁed ac-
cording to current GVHD status and IST: group A, active/un-
treated extensive cGVHD; group B, active cGVHD on high dose
IST; group C, quiescent cGVHD on low IST; group D, tolerant
patients off IST. PBMC were isolated for immunophenotype and
gene expression studies.
Number of CD4 T cells and CD4:CD8 ratio were lower in all
groups compared to controls (p0.02 and 0.03). HLA-DR was
increased in all patients (p0.000) ranging from 14% to 20% of
CD4 and from 34% to 41% of CD8.
The %CD4CD25CD127lo Treg cells in PBL in tolerant was
higher (9.33%) compared to active and quiescent patients (5.9%
and 6.3% respectively, p0.05) and to controls (7.2%, pns).
Gene expression in PBMC was evaluated by real time PCR for
IFNG, IL2RA, IL7R IL10, TGFB and FOXP3. IFNG was in-
creased in active patients compared to controls (p0.02), it tended
to be lower than controls in quiescent and similar to controls in
tolerant patients. IFNG in patients overall correlated with the
%CD8DR (p0.04). IL10 expression was increased in all pa-
tients compared to controls (p0.02) with the highest levels in
quiescent cGVHD. IL10 was lower in tolerant but remained
higher than controls (p0.02). TGFB expression was increased
only in patients with active disease on high dose IST (p0.05).
IL7R was decreased in all patients (p0.000).
FOXP3 expression was signiﬁcantly lower in active and quiescent
cGVHD (p0.02) compared to controls. Average FOXP3 in tol-
erant was similar to controls, however the range for tolerant was
skewed towards below normal levels.
These studies support the theory that FOXP3 plays an important
role in induction of tolerance, but they also suggest a signiﬁcant
role for other immune regulator molecules including TGFB and
IL10. Additional studies will be necessary to more clearly deﬁne
molecular and functional interactions between these regulatory
factors.
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VB TCR USAGE AND TREG CD4CD25CTLA4/- CELLS IN ACUTE
AND CHRONIC GRAFT VERSUS HOST DISEASE, (GVHD), PATIENTS
SUBMITTED TO EXTRACORPOREALPHOTOTHERAPY, (ECP): A STUDY
TO EVALUATE THEIR PREDICTIVE SIGNIFICANCE ON THE GVHD OUT-
COME
Tassi, C.1, Arpinati, M.2, Tazzari, P.L.1, Ricci, F.1, Conte, R.1 1Servi-
zio Medicina Trasfusionale-Policlinico Sant’Orsola, Bologna, Italy; 2Is-
tituto Di Ematologia Ed Oncologia Seragnoli-Policlinico Sant’Orsola,
Bologna, Italy.
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